The global meningococcal vaccine market was valued at $1,935.5 million in 2018, and is projected to reach $4,192.5 million by 2026, registering a CAGR of 9.5% from 2019 to 2026. Invasive meningococcal disease (IMD) is a bacterial infection caused by a gram-negative coccus, Neisseria meningitidis, which includes spectrum of infections including meningitis, bacteremia (meningococcemia), and bacteremia pneumonia. Although meningococcal disease is rare but is associated with high fatality of up to 50% if left untreated and often results in serious complications thereafter. Meningococcal meningitis results in infection of the lining of the brain and spinal cord and also has a potential to cause large epidemics as well as endemics. The disease is generally transmitted through direct contact with droplets of respiratory or throat secretions from patients or asymptomatic carriers. Various serotypes of N. meningitidis are included in 12 serogroups of which only 5 serogroups including A, B, C, W, and Y are responsible for the majority of disease worldwide. However, circulation of these serogroups is highly unpredictable and varies over time across age groups and geographies. Vaccines for each of these serogroups are available in the market.
It is estimated that the meningococcal vaccine market is expected to experience significant market growth during the forecast period as there has been an increase in adoption in several countries across the globe in their national immunization programs. In addition, surge in meningococcal outbreaks in several countries has led to upsurge in demand for meningococcal vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products due to contamination are expected to impede market growth. In contrast, high population base in emerging markets and global increase in healthcare spending provides significant growth opportunities for the meningococcal vaccine market.
The global meningococcal vaccine market is segmented on the basis of serogroup, vaccine type, end user, and region. The serogroups covered in the study include MenACWY, MenB/BC, MenC, MenAC, and MenA. Depending on vaccine type, the market is classified into conjugate, polysaccharide, and subcapsular. According to end user, the market is segmented into pediatric, adults, and travelers. By region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, the Netherlands, Spain, and rest of Europe), Asia-Pacific (China, Australia, and rest of Asia-Pacific), and LAMEA (Latin America, the Middle East, and Africa).
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Vaccine Serotype
By Vaccine Type
By End User
By Region
LIST OF KEY PLAYERS PROFILED IN THE REPORT
It is estimated that the meningococcal vaccine market is expected to experience significant market growth during the forecast period as there has been an increase in adoption in several countries across the globe in their national immunization programs. In addition, surge in meningococcal outbreaks in several countries has led to upsurge in demand for meningococcal vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products due to contamination are expected to impede market growth. In contrast, high population base in emerging markets and global increase in healthcare spending provides significant growth opportunities for the meningococcal vaccine market.
The global meningococcal vaccine market is segmented on the basis of serogroup, vaccine type, end user, and region. The serogroups covered in the study include MenACWY, MenB/BC, MenC, MenAC, and MenA. Depending on vaccine type, the market is classified into conjugate, polysaccharide, and subcapsular. According to end user, the market is segmented into pediatric, adults, and travelers. By region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, the Netherlands, Spain, and rest of Europe), Asia-Pacific (China, Australia, and rest of Asia-Pacific), and LAMEA (Latin America, the Middle East, and Africa).
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Vaccine Serotype
- MenACWY
- MenB & MenBC
- MenC
- MenA
- MenAC
By Vaccine Type
- Conjugate
- Polysaccharide
- Subcapsular
By End User
- Pediatric
- Adult
- Travelers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- the Netherlands
- Spain
- Rest of Europe
- Asia Pacific
- China
- Australia
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle-East
- Africa
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Bio-Manguinhos
- Bio-Med Pvt. Limited
- Chongqing Zhifei Biological Products Co., Ltd.
- GlaxoSmithKline Plc
- Hualan Biological Engineering Inc.
- Incepta Pharmaceuticals Ltd.
- Pfizer INC
- Sanofi S.A.
- Serum Institute of India Pvt. Ltd
- Walvax Biotechnology Co., Ltd.
Frequently Asked Questions about the Global Meningococcal Vaccine Market
What is the estimated value of the Global Meningococcal Vaccine Market?
What is the growth rate of the Global Meningococcal Vaccine Market?
What is the forecasted size of the Global Meningococcal Vaccine Market?
Who are the key companies in the Global Meningococcal Vaccine Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 197 |
| Published | April 2020 |
| Forecast Period | 2018 - 2026 |
| Estimated Market Value ( USD | $ 1935.5 million |
| Forecasted Market Value ( USD | $ 4192.5 million |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Meningococcal Vaccine Market, by Vaccine Serotype
Chapter 5: Meningococcal Vaccine Market, by Vaccine Type
Chapter 6: Meningococcal Vaccine Market, by End-user
Chapter 7: Meningococcal Vaccine Market by Region
Chapter 8: Company Profiles
Executive Summary
According to the report titled, 'Meningococcal Vaccine Market by Vaccine Serotype, Vaccine Type, and End User: Opportunity Analysis and Industry Forecast, 2018-2026', the global meningococcal vaccines market size was valued at $1,935.54 million in 2018, and is projected to reach $4.19 billion by 2026, registering a CAGR of 9.5% from 2019 to 2026.Bacterial infections can be prevented by immunization and therefore, immunization is crucial. Neisseria meningitidis, is a virus that causes diseases such as meningitis, bacteremia (meningococcemia), and bacteremia pneumonia. However, these infectious diseases can be prevented by the use of meningococcal vaccines. Meningococcal vaccines are administered to both children and adults in a pattern of two doses to ensure complete immunization. There are three different types of meningococcal vaccines such as conjugate, polysaccharide, and subcapsular meningococcal vaccines.
Rise in immunization programs worldwide is the major factor that boost the growth of the meningococcal vaccine market. In addition, factors such as surge in awareness related to the use of meningococcal vaccines and increase in adoption of vaccination across the globe fuel the growth of the meningococcal vaccine market. However, high monetary inputs associated with manufacture of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the meningococcal vaccine market growth during the forecast period.
The global meningococcal vaccine market is segmented on the basis of serotype, vaccine types, and end user. On the basis of serotype, the market is classified into Men ACYW, Men B/BC, Men C/CY, Men AC, and Men A. By vaccine type, it is divided into conjugate, polysaccharide, and subcapsular. On the basis of end user, it is segmented into pediatric, adult, and traveler. Based on region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, the UK, Spain, France, the Netherland, and rest of Europe), Asia-Pacific(China, Australia, and rest of Asia-Pacific), and LAMEA (Latin America.
Based on Serotypes, the meningococcal vaccine segment constituted for the major share of the meningococcal vaccine market and is expected to experience rapid growth during the forecast period as these vaccines exhibit increase in adoption in several countries and inclusion of vaccines in their national immunization programs. Moreover, Meningococcal meningitis outbreaks in several countries has led to upsurge in demand for meningococcal vaccines, which further swelled up the growth of the market is another reason that boosts the growth of the meningococcal vaccine market.
On the basis of region, North America acquired a major share owing to easy availability of meningococcal vaccines, presence of skilled healthcare experts, and presence of major key players that offer meningococcal vaccines. The Asia-Pacific region is expected to grow at the fastest rate during the forecast period due to surge in awareness related to importance of immunization, presence of large population, and rise in disposable income.
The developing economies offer lucrative opportunities for meningococcal vaccine providers to expand their business. The constantly evolving healthcare industry drives the growth of the market in the developing economies such as Africa, China, and others ca, the Middle East, and Africa).
Key Findings Of The Study
As per the serotype, the MenACWY vaccine segment is accounted for the highest market share of 54% in 2018 and is anticipated to grow at a CAGR of 11.7% during the forecast period.
On the basis of the vaccine type, the conjugate vaccine segment accounted for the largest market share and is anticipated to be the fastest growing segment at a CAGR of 10.2%.
By end user, the hospitals & clinics segment is expected to grow at the highest CAGR of 11.6% from 2019 to 2026, in terms of value.
Region wise, North America was the major shareholder and accounted for 49.84% of the meningococcal vaccine market share in 2018.
Comprehensive competitive analysis and profiles of major market players such as Bio-Manguinhos, Bio-Med Pvt. Limited, Chongqing Zhifei Biological Products Co., Ltd., GlaxoSmithKline Plc, Hualan Biological Engineering Inc., Incepta Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd, and Walvax Biotechnology Co., Ltd. are provided in this report.
Companies Mentioned
- Bio-Manguinhos
- Bio-Med Pvt. Limited
- Chongqing Zhifei Biological Products Co. Ltd.
- GlaxoSmithKline Plc
- Hualan Biological Engineering Inc. Inc.pta Pharmaceuticals Ltd.
- Pfizer Inc.
- Sanofi S.A.
- Serum Institute of India Pvt. Ltd
- Walvax Biotechnology Co. Lt
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
